Achievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments

Ye Seul Yang, Seo Young Lee, Jung Sun Kim, Kyung Mook Choi, Kang Wook Lee, Sang Chol Lee, Jung Rae Cho, Seung Jin Oh, Ji Hyun Kim, Sung Hee Choi

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)


    Background: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/ EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia.

    Original languageEnglish
    Pages (from-to)367-376
    Number of pages10
    JournalEndocrinology and Metabolism
    Issue number2
    Publication statusPublished - 2020

    Bibliographical note

    Publisher Copyright:
    © 2020 Korean Endocrine Society


    • Cholesterol
    • Dyslipidemias
    • Hydroxymethylglutaryl-CoA reductase inhibitors
    • Korea
    • LDL
    • Practice guideline
    • Risk assessment

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology


    Dive into the research topics of 'Achievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments'. Together they form a unique fingerprint.

    Cite this